BRPI0412902A - compostos contendo imidazo substituìdo por oxima - Google Patents

compostos contendo imidazo substituìdo por oxima

Info

Publication number
BRPI0412902A
BRPI0412902A BRPI0412902-4A BRPI0412902A BRPI0412902A BR PI0412902 A BRPI0412902 A BR PI0412902A BR PI0412902 A BRPI0412902 A BR PI0412902A BR PI0412902 A BRPI0412902 A BR PI0412902A
Authority
BR
Brazil
Prior art keywords
compounds
oxime
containing compounds
substituted imidazo
imidazo
Prior art date
Application number
BRPI0412902-4A
Other languages
English (en)
Inventor
Tushar Kshirsagar
David T Amos
Joseph F Dellaria Jr
Philip D Heppner
Scott E Langer
Bernhard M Zimmermann
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of BRPI0412902A publication Critical patent/BRPI0412902A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTOS CONTENDO IMIDAZO SUBSTITUìDO POR OXIMA". A presente invenção refere-se a compostos contendo imidazo (por exemplo, imidazoquinolinas, imidazonaftiridinas e imidazopiridinas) com um substituinte de oxima na posição 1, composições farmacêuticas contendo os compostos, intermediários e métodos de uso destes compostos como imunomoduladores, para induzir biossíntese de citocina em animais e no tratamento de doenças incluindo doenças virais e neoplásicas são descritos.
BRPI0412902-4A 2003-08-12 2004-08-12 compostos contendo imidazo substituìdo por oxima BRPI0412902A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49460503P 2003-08-12 2003-08-12
US49460803P 2003-08-12 2003-08-12
PCT/US2004/026065 WO2005018551A2 (en) 2003-08-12 2004-08-12 Oxime substituted imidazo-containing compounds

Publications (1)

Publication Number Publication Date
BRPI0412902A true BRPI0412902A (pt) 2006-09-26

Family

ID=34221362

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0412902-4A BRPI0412902A (pt) 2003-08-12 2004-08-12 compostos contendo imidazo substituìdo por oxima
BRPI0413558-0A BRPI0413558A (pt) 2003-08-12 2004-08-12 compostos contendo imidazo substituìdo por hidroxilamina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0413558-0A BRPI0413558A (pt) 2003-08-12 2004-08-12 compostos contendo imidazo substituìdo por hidroxilamina

Country Status (10)

Country Link
US (2) US8673932B2 (pt)
EP (2) EP1653914A4 (pt)
JP (2) JP2007502293A (pt)
AR (2) AR045261A1 (pt)
AU (2) AU2004266641A1 (pt)
BR (2) BRPI0412902A (pt)
CA (2) CA2535120A1 (pt)
MX (2) MXPA06001669A (pt)
TW (2) TW200524927A (pt)
WO (2) WO2005018556A2 (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
JP2005538057A (ja) 2002-06-07 2005-12-15 スリーエム イノベイティブ プロパティズ カンパニー エーテル置換イミダゾピリジン
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
MXPA06001669A (es) 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
NZ545412A (en) * 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) * 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
KR101494056B1 (ko) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
CN1906192A (zh) * 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
WO2005048933A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2005076783A2 (en) 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) * 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
AU2005283085B2 (en) 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
JP5209312B2 (ja) 2004-09-02 2013-06-12 スリーエム イノベイティブ プロパティズ カンパニー １−アルコキシ１ｈ−イミダゾ環系および方法
JP2008523076A (ja) * 2004-12-08 2008-07-03 スリーエム イノベイティブ プロパティズ カンパニー 免疫調節性の組成物、合剤、および方法
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005321912B2 (en) 2004-12-30 2012-04-05 3M Innovative Properties Company Treatment for cutaneous metastases
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
CA2597446A1 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
AU2006223634A1 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1851218A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006287270A1 (en) * 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
CN101330916A (zh) * 2005-12-16 2008-12-24 科勒制药集团公司 经取代的咪唑并喹啉、咪唑并萘啶和咪唑并吡啶、其组合物及其方法
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
HUE029309T2 (en) 2006-03-17 2017-02-28 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as novel physiologically useful nitroxyl donors
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
LT2606047T (lt) 2010-08-17 2017-04-10 3M Innovative Properties Company Imuninio atsako modifikatoriaus junginio lipidizuotos kompozicijos, sudėtys ir būdai
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CA2838023C (en) 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
AU2014203896B2 (en) 2013-01-07 2018-05-31 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous T cell lymphoma
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US10118925B2 (en) 2015-08-31 2018-11-06 3M Innovative Properties Company Imidazo[4,5-c] ring compounds containing substituted guanidine groups
CN108026092B (zh) 2015-08-31 2021-01-26 3M创新有限公司 胍取代的咪唑并[4,5-c]环化合物
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
EP3889158B1 (en) 2016-08-26 2024-07-03 Solventum Intellectual Properties Company Fused [1,2]imidazo[4,5-c] ring compounds substituted with guanidino groups
EP3589631B1 (en) 2017-03-01 2021-07-21 3M Innovative Properties Company Imidazo[4,5-c]ring compounds containing guanidine substituted benzamide groups
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN111788202B (zh) 2018-02-28 2024-03-01 3M创新有限公司 具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
BR112020022595A2 (pt) 2018-05-23 2021-02-09 Pfizer Inc. anticorpos específicos para gucy2c e usos dos mesmos
DK3797121T3 (da) 2018-05-23 2024-07-08 Pfizer Antistoffer, der er specifikke for CD3, og anvendelser deraf
CA3101277A1 (en) 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US12024514B2 (en) 2018-11-26 2024-07-02 Solventum Intellectual Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
EP3980415A1 (en) 2019-06-06 2022-04-13 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20220194935A1 (en) 2019-06-12 2022-06-23 3M Innovative Properties Company Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
US11702474B2 (en) 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CA3184740A1 (en) * 2020-07-08 2022-01-13 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
CA3189590A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Family Cites Families (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
DE1645976A1 (de) 1966-06-18 1971-01-21 Ajinomoto Kk Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin
ZA704419B (en) 1969-07-21 1971-04-28 Ici Australia Ltd Injectable aqueous solutions of tetramisole
US3692907A (en) 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
US4006237A (en) 1973-10-11 1977-02-01 Beecham Group Limited Tetrahydrocarbostyril derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3891660A (en) 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US3899508A (en) 1974-04-12 1975-08-12 Lilly Co Eli 5-(2-Aminophenyl)pyrazole-3-carboxylic acids and esters thereof
DE2423389A1 (de) 1974-05-14 1975-12-04 Hoechst Ag Arzneimittel mit psychotroper wirkung und verfahren zu ihrer herstellung
US4381344A (en) 1980-04-25 1983-04-26 Burroughs Wellcome Co. Process for producing deoxyribosides using bacterial phosphorylase
DE3204126A1 (de) 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4758574A (en) 1982-05-03 1988-07-19 Eli Lilly And Company 2-phenylimidazio (4,5-c) pyridines
US4563525A (en) 1983-05-31 1986-01-07 Ici Americas Inc. Process for preparing pyrazolopyridine compounds
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JPS61112075A (ja) 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4593821A (en) 1985-04-25 1986-06-10 Laros Equipment Company, Inc. Belt separator for blow molding parts
US4698346A (en) 1985-05-08 1987-10-06 Usv Pharmaceutical Corporation Thiazolo[5,4-h]quinoline compounds useful as anti-allergy agents
US4826830A (en) 1985-07-31 1989-05-02 Jui Han Topical application of glyciphosphoramide
CA1306260C (en) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
HU197019B (en) 1985-11-12 1989-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing thiqzolo (4,5-c) quinoline derivatives and pharmaceuticals comprising same
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
CA1287061C (en) 1986-06-27 1991-07-30 F. Hoffmann-La Roche Ag Pyridine ethanolamine derivatives
US5500228A (en) 1987-05-26 1996-03-19 American Cyanamid Company Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
US4880779A (en) 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5736553A (en) 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
DK0385630T3 (da) 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5750134A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
KR970004802B1 (ko) 1990-04-30 1997-04-04 아이시스 파마슈티칼스, 인코포레이티드 올리고뉴클레오티드를 이용한 아라키돈산 대사조절
EP0461040A1 (fr) 1990-06-08 1991-12-11 Roussel Uclaf Dérivés de l'imidazole, leur procédé de préparation, les intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant
CA2093132C (en) * 1990-10-05 2002-02-26 John F. Gerster Process for the preparation of imidazo[4,5-c]quinolin-4-amines
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5342784A (en) 1991-04-12 1994-08-30 Mitsubishi Paper Mills Limited Electrophotographic lithographic printing plate
JPH04327587A (ja) 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
TW300219B (pt) 1991-09-14 1997-03-11 Hoechst Ag
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5378848A (en) 1992-02-12 1995-01-03 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
EP0622681B1 (en) 1993-04-27 1997-10-01 Agfa-Gevaert N.V. Process for incorporation of a water-insoluble substance into a hydrophilic layer
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
KR100341341B1 (ko) * 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
CA2131680C (en) 1993-09-17 2006-11-07 Gerhard Stucky Process for preparing imidazopyridine derivatives
US5837809A (en) 1995-08-11 1998-11-17 Oregon Health Sciences University Mammalian opioid receptor ligand and uses
JPH07163368A (ja) 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えｄｎａとその組換えｄｎａを含む形質転換体
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5612377A (en) 1994-08-04 1997-03-18 Minnesota Mining And Manufacturing Company Method of inhibiting leukotriene biosynthesis
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
GB9420168D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
FR2732605B1 (fr) 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US5766789A (en) 1995-09-29 1998-06-16 Energetics Systems Corporation Electrical energy devices
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
US5939047A (en) 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US5861268A (en) 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
TW552261B (en) 1996-07-03 2003-09-11 Japan Energy Corp Novel purine derivative
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
HUP9904665A3 (en) 1996-10-25 2000-11-28 Minnesota Mining And Mfg Co Sa Immune response modifier compounds for treatment of th2 mediated and related diseases
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4101302B2 (ja) * 1997-01-09 2008-06-18 テルモ株式会社 新規アミド誘導体および合成中間体
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6123957A (en) 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US6077349A (en) 1997-08-20 2000-06-20 Sony Corporation Method and apparatus for manufacturing disc-shaped recording medium
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6667348B2 (en) * 1997-10-21 2003-12-23 Exxonmobil Research And Engineering Company Throat and cone gas injector and gas distribution grid for slurry reactor {CJB-0004}
CA2311742C (en) 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
US6121323A (en) 1997-12-03 2000-09-19 3M Innovative Properties Company Bishydroxyureas
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JPH11222432A (ja) 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
GB9804377D0 (en) 1998-03-03 1998-04-22 Speights Limited Lighting device
US6114058A (en) 1998-05-26 2000-09-05 Siemens Westinghouse Power Corporation Iron aluminide alloy container for solid oxide fuel cells
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US5962636A (en) 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
NZ512628A (en) 1999-01-08 2004-03-26 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1495758A3 (en) 1999-01-08 2005-04-13 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6294271B1 (en) 1999-02-12 2001-09-25 Shin-Etsu Chemical Co., Ltd. Flip-chip type semiconductor device sealing material and flip-chip type semiconductor device
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
AU777409B2 (en) 1999-04-12 2004-10-14 Lexicon Pharmaceuticals, Inc. Novel lipoxygenase proteins and polynucleotides encoding the same
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
EP2314693A3 (en) 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
MXPA02004193A (es) 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6313156B1 (en) 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
US20040023870A1 (en) 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
EP1256582A1 (en) 2000-02-09 2002-11-13 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
EP1265840A2 (en) 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
US20010046968A1 (en) 2000-03-23 2001-11-29 Zagon Ian S. Opioid growth factor modulates angiogenesis
JP3481930B2 (ja) 2000-03-30 2003-12-22 塩野義製薬株式会社 縮合イミダゾピリジン誘導体の新規製造法および新規結晶形
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
DE10020465A1 (de) 2000-04-26 2001-11-08 Osram Opto Semiconductors Gmbh Strahlungsemittierendes Halbleiterbauelement mit Lumineszenzkonversionselement
AU2001264753A1 (en) 2000-05-19 2001-12-03 Millennium Pharmaceuticals, Inc. 46638, a putative family member of human lipoxygenase
DE10029580C1 (de) 2000-06-15 2002-01-10 Ferton Holding Sa Vorrichtung zum Entfernen von Körpersteinen mit einem intrakorporalen Lithotripter
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
JP2005500806A (ja) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
JP2002145777A (ja) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
CZ20031587A3 (cs) 2000-12-07 2004-01-14 Aoyama Seisakusho Co., Ltd. Způsob vypékání ocelových částí produktu
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
EP1360486A2 (en) 2000-12-08 2003-11-12 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
ATE463505T1 (de) 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US20020193729A1 (en) 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
US6627639B2 (en) 2001-04-26 2003-09-30 Wyeth Uses for indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino-[2,3-e]indole
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
KR20040027878A (ko) 2001-07-16 2004-04-01 시오노기 앤드 컴파니, 리미티드 아미딘 유도체의 제조 방법
CA2458876A1 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
DE60230340D1 (de) 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
US20050009858A1 (en) 2001-11-17 2005-01-13 Martinez-Colon Maria I Imiquimod therapies
CN1300165C (zh) 2001-11-27 2007-02-14 安那迪斯药品股份有限公司 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
WO2004080430A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods of improving skin quality
CA2467828C (en) * 2001-11-29 2011-10-04 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6775514B2 (en) 2002-01-11 2004-08-10 Xerox Corporation Substrate size monitoring system for use in copier/printers
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US20050281813A1 (en) 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
PT1478327E (pt) * 2002-02-22 2015-08-04 Meda Ab Método de redução e tratamento de imunossupressão induzida por uvb
US20030185835A1 (en) 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
DE60328676D1 (de) 2002-04-30 2009-09-17 Unigen Pharmaceuticals Inc Formulierung eines gemisches aus flavonoiden und flavanen mit freiem b ring als therapeutisches mittel
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
JP2005538057A (ja) 2002-06-07 2005-12-15 スリーエム イノベイティブ プロパティズ カンパニー エーテル置換イミダゾピリジン
DK1543002T3 (da) * 2002-07-23 2006-12-27 Teva Gyogyszergyar Zartkoeruee Fremstilling af 1H-imidazo (4,5-c) quinolin-4-aminer via 1H-imidazo (4,5-c) quinolin-4-phtalimid mellemprodukter
PL374866A1 (en) * 2002-07-26 2005-11-14 Teva Gyogyszergyar Zartköruen Muködo Reszvenytarsasag Preparation of 1h-imidazo [4,5-c] quinolin-4-amines via novel 1h-imidazo [4,5-c] quinolin-4-cyano and 1h-imidazo [4,5-c] quinolin-4-carboxamide intermediates
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
WO2004053452A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
WO2004080398A2 (en) 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
AU2004220465A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
JP2006523212A (ja) 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー 皮膚病変の診断方法
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004244962A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
WO2004096144A2 (en) 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
WO2004110992A2 (en) 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
WO2004110991A2 (en) 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
MY157827A (en) 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
US20050106300A1 (en) 2003-06-30 2005-05-19 Purdue Research Foundation Method for producing a material having an increased solubility in alcohol
WO2005016273A2 (en) 2003-08-05 2005-02-24 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
MXPA06001669A (es) * 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
EP2939693A1 (en) 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
AU2004266162A1 (en) 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
ATE465742T1 (de) 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc Tlr7-liganden zur behandlung von hepatitis c
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005029037A2 (en) 2003-09-17 2005-03-31 3M Innovative Properties Company Selective modulation of tlr gene expression
WO2005033049A2 (en) * 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20090075980A1 (en) 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1680080A4 (en) 2003-10-31 2007-10-31 3M Innovative Properties Co NEUTROPHILIC ACTIVATION THROUGH COMPOUNDS TO MODIFY THE IMMUNE RESPONSE
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
ITMI20032121A1 (it) 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
WO2005048933A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CU23404A1 (es) 2003-11-19 2009-08-04 Ct Ingenieria Genetica Biotech Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
US8778963B2 (en) 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
US20050226878A1 (en) 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JP2007513165A (ja) 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物を含む併用薬および治療方法
WO2005076783A2 (en) 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
CA2552101A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
WO2005065678A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
EP1699398A4 (en) 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20070166384A1 (en) 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
US20050267145A1 (en) 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006093514A2 (en) 2004-06-18 2006-09-08 3M Innovative Properties Company Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
WO2006026760A2 (en) 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
JP2008523084A (ja) 2004-12-08 2008-07-03 スリーエム イノベイティブ プロパティズ カンパニー 免疫賦活用合剤および方法
JP2008523076A (ja) 2004-12-08 2008-07-03 スリーエム イノベイティブ プロパティズ カンパニー 免疫調節性の組成物、合剤、および方法
JP2008526757A (ja) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤製剤および方法
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1846405A2 (en) * 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
JP2008530112A (ja) 2005-02-11 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 置換縮合［１，２］イミダゾ「４，５−ｃ］環化合物および方法
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
US8138173B2 (en) 2005-04-01 2012-03-20 3M Innovative Properties Company Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US8168802B2 (en) 2005-04-01 2012-05-01 3M Innovative Properties Company Ring closing and related methods and intermediates
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002414A (es) 2005-09-02 2008-03-27 Pfizer 1h-imidazopiridinas sustituidas con hidroxi y procedimientos.
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007035935A1 (en) 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007062043A1 (en) 2005-11-23 2007-05-31 Coley Pharmaceutical Group Inc. Method of activating murine toll-like receptor 8
CN101330916A (zh) 2005-12-16 2008-12-24 科勒制药集团公司 经取代的咪唑并喹啉、咪唑并萘啶和咪唑并吡啶、其组合物及其方法
WO2007079171A2 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Treatment for hodgkin's lymphoma
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
WO2007079169A2 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Treatment for acute myeloid leukemia
WO2007079202A2 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Treatment for acute lymhoblastic leukemia
WO2007079146A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc Treatment for non-hodgkin's lymphoma
WO2007079203A2 (en) 2005-12-28 2007-07-12 3M Innovative Properties Company Treatment for cutaneous t cell lymphoma
US20090306388A1 (en) 2006-02-10 2009-12-10 Pfizer Inc. Method for substituted ih-imidazo[4,5-c] pyridines
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007106852A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
WO2007143526A2 (en) 2006-06-05 2007-12-13 Coley Pharmaceutical Group, Inc. Substituted tetrahydroimidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
WO2008036312A1 (en) 2006-09-19 2008-03-27 Coley Pharmaceutical Group, Inc. Fungicidal methods using immune response modifier compounds
WO2008045543A1 (en) 2006-10-13 2008-04-17 Coley Pharmaceutical Group, Inc. Substituted 4h-imidazo [4, 5, 1-ij] [1, 6] naphthyridine-9-amines and their pharmaceutical use

Also Published As

Publication number Publication date
JP2007502288A (ja) 2007-02-08
AU2004266658A1 (en) 2005-03-03
EP1653955A4 (en) 2009-07-29
TW200524927A (en) 2005-08-01
WO2005018556A3 (en) 2005-09-29
MXPA06001669A (es) 2006-04-28
EP1653914A4 (en) 2008-10-29
US7648997B2 (en) 2010-01-19
WO2005018551A3 (en) 2006-05-11
AU2004266641A1 (en) 2005-03-03
WO2005018551A2 (en) 2005-03-03
CA2535117A1 (en) 2005-03-03
AR045261A1 (es) 2005-10-19
US8673932B2 (en) 2014-03-18
AR045260A1 (es) 2005-10-19
JP2007502293A (ja) 2007-02-08
MXPA06001674A (es) 2006-05-12
BRPI0413558A (pt) 2006-10-17
US20080114019A1 (en) 2008-05-15
US20070066639A1 (en) 2007-03-22
TW200510412A (en) 2005-03-16
EP1653955A2 (en) 2006-05-10
CA2535120A1 (en) 2005-03-03
WO2005018556A2 (en) 2005-03-03
EP1653914A2 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
BRPI0413558A (pt) compostos contendo imidazo substituìdo por hidroxilamina
BRPI0414867A (pt) pirazolopiridinas e seus análogos
CR9781A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
BRPI0413998A (pt) imidazoquinolinas arilóxi e arilalquilenóxi substituìdas
TW200639172A (en) Pyrazolopyridines and analogs thereof
BRPI0408125A (pt) 1-amino 1h-imidazoquinolinas
BRPI0414856A (pt) imidazoquinolinas alcóxi-substituìdas
WO2006107853A3 (en) Pyrazolopyridine-1,4-diamines and analogs thereof
CR8254A (es) [1,8] naftidrin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
WO2005048933A3 (en) Oxime substituted imidazo ring compounds
WO2005048945A3 (en) Hydroxylamine substituted imidazo ring compounds
WO2008030511A3 (en) Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
ATE555786T1 (de) 1-alkoxy 1h-imidazo-ringsysteme und verfahren
WO2006026760A3 (en) 1-amino imidazo-containing compounds and methods
BRPI0512683A (pt) compostos anti-virais
WO2006091394A3 (en) Substituted imidazoquinolines and imidazonaphthyridines
WO2006086633A3 (en) Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
WO2006086449A3 (en) Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
HRP20070043A2 (hr) Antivirusna sredstva
WO2006086634A3 (en) Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.